C Diff Drug Development

New study data for Destiny Pharma's NTCD-M3 offers further validation of its potential to prevent C. difficile infection recurrence as it progresses towards Phase 3 clinical trials.

Charlton Athletic owner Thomas Sandgaard has confirmed negotiations are ongoing to sign Crystal Palace attacker Jesurun Rak-Sakyi on loan.

The microbiota-based live therapeutic had a 68.3% success rate when administered following antibiotic treatment, versus a 55% success rate in a placebo group.

Clostridioides difficile (Cdiff) infection (CDI) continues to be the leading threat of nosocomial deaths worldwide and a major burden on health-care systems. Broad-spectrum antibiotics eradicate the normal gut microbiome, killing protective commensal bacteria and increasing CDI recurre …

C. difficile infection (CDI) is a highly inflammatory disease mediated by the production of two large toxins that weaken the intestinal epithelium and cause extensive colonic tissue damage. Antibiotic alternative therapies for CDI are urgently needed as current antibiotic regimens prolong the pertur …

Reduction of Clostridioides difficile infection (CDI) recurrence is an essential endpoint for CDI-directed antibiotic development that is often not evaluated until Phase III trials. The purpose of this project was to use a functional and metagenomic approach to predict the potential anti-CDI recurre …

Probiotics are live microorganisms that, when administered in adequate amounts, provide health benefits to the host. Some strains of the probiotic Lactobacillus reuteri (L. reuteri) have both antimicrobial and anti-inflammatory properties that may be exploited for the treatment and pre …

Menlo Park, CA, July 14, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” "we," or the “Company”) today provided an update...

Long-term treatment of functional dyspepsia with proton-pump inhibitors can alter the gut microbiome. A new pilot randomized, double-blind, placebo-controlled trial suggests the potential of spore-forming probiotics in patients with functional dyspepsia.

Clostridioides difficile infection is a global public health threat. Extensive in vitro assays using clinical isolates have identified micrococcin P2 (MP2, 1) as a particularly effective anti-C. difficile agent. MP2 possesses a mode of action that differs from other antib …

Shows potent and rapid antibacterial activity against clinical isolates in Europe and Korea both CDL200,  a novel endolysin pipeline for the treatment of Clostridioides difficile Infection (CDI) The world's first endolysin in capsule formulation to be administered orally BOSTON and SEOUL, South Korea, July 12, 2022 /PRNewswire/ -- iNtRON Biotechnology ("iNtRON", www.intodeworld.com) announc...

While there's risk, Seres Therapeutics (MCRB) is well positioned for share price gain based on several factors. Click here to know those factors.

Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease Melbourne, Australia, July 07, 2022: Immuron... | July 7, 2022

After decades of research, gut microbiome therapies are on the cusp of reaching the market. Here are five of the companies that are closest to hitting this historic milestone.

Microbiome pioneer Seres Therapeutics faced numerous setbacks throughout the years in numerous fields, most prominently for its lead program in C. difficile infections. But the biotech has plotted a comeback after a major flop six years ago, and is confident enough to start seeking cash ahead of a possible market

Paul Feuerstadt, MD, FACG, AGAF, discussed research into the novel C. difficile treatment RBX2660 and what investigators have found about its efficacy in key subgroup analyses.

Patients with recurrent Clostridioides difficile infection saw improvements in fecal microbiome and bile acid after treatment with the investigational microbiota-based live biotherapeutic RBX2660.

Clostridium difficile (C.difficile) is an exclusively anaerobic, spore-forming, and Gram-positive pathogen that is the most common cause of nosocomial diarrhea and is becoming increasingly prevalent in the community. Because C. difficile is strictly anaerobic, spores that can survive f …

Eric Shaff, president and CEO of Seres Therapeutics, discusses the confirmatory trial findings for SER-109. Seres is filing a Biologics License Application for the recurrent C diff therapy.

Eric Schaff, president and CEO of Seres Therapeutics, discusses the confirmatory trial findings for SER-109. Seres is filing a Biologics License Application for the recurrent C diff therapy.

Essential oils of wild oregano, black pepper and garlic are candidates for adjunctive therapeutics in the treatment of CDI. Oregano oil should certainly be preferred due to the lack of selectivity of action in relation to the ribotype, the strength of the produced biofilm and/or antibiotic-susceptib …

Patients with recurrent C difficile infection receiving SER-109 experienced reduced rates of infection as early as 4 weeks following treatment.

Eric Schaff, president and CEO of Seres Therapeutics, discusses the confirmatory trial findings for SER-109. Seres is filing a Biologics License Application for the recurrent C diff therapy.

Paul Feuerstadt, MD, on the pooled analysis that compared medical history and demographics

.@PhaseGenomics received funding from the @GatesFoundation and @NIAIDFunding to develop an atlas of #phage-bacteria interactions and identify phages that can be used in therapeutic settings such as #Cdiff, #UlcerativeColitis, and #CrohnsDisease.📍 https://t.co/NZmoL9Ltdo pic.twitter.com/kWpXRwokqw— Science in Seattle (@science_seattle) June 13, 2022

Innovative efforts at the University of Virginia School of Medicine to use a harmless amoeba to protect children from dangerous infections has won critical financial support from The Hartwell …

SER-109, the investigational oral microbiome therapeutic from Seres, reduced C diff recurrence by 91.3% in at-risk populations.